Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer
Retrieved on:
Thursday, November 18, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Mayo Clinic, Principia, Head, University School, Endocrinology, Cancer, IL-6, Inflammation, Clinical professor, Therapy, All India Institute of Medical Sciences, New Delhi, Immunology, Cytokine, Clinical research, Development, India, NYU, B cell, Â, Antibody, Medicine, Internal medicine, Southern Illinois University School of Medicine, Fibrosis, National Institutes of Health Clinical Research Training Program, All India Institute of Speech and Hearing, Degenerative disease, Pharmaceutical industry
Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced the appointment of Puneet S. Arora, M.D.
Key Points:
- Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced the appointment of Puneet S. Arora, M.D.
- As a highly regarded physician-scientist and drug developer, Puneets experience in inflammation and immunology will be instrumental to Lassen as we initiate our clinical program for LASN01, our first-in-class anti-IL-11R antibody, said Mark Barrett Chief Executive Officer of Lassen Therapeutics.
- Dr. Arora managed clinical development for lead programs including early translational development and proof of concept through late development and regulatory submissions.
- Lassen is pursuing compelling targets and novel mechanisms of action with the potential to result in important new therapeutics for patients with limited treatment options.